|
|
Enfuvirtide (T-20) Updated March, 2009 Roy M. Gulick, MD, MPH, Philip A. Chan, MD, Rami Kantor, MD
In the past couple decades, antiretroviral therapy for HIV/AIDS has been designed to inhibit two key enzymes, reverse transcriptase (RT) and protease. Despite the immense success of treatment regimens with these drugs and the morbidity and mortality reductions in HIV infected persons (81, 85, 103), the durability of viral suppression is often limited. Contributing factors include poor penetration into protected sites containing a reservoir of HIV (54, 63), alterations in the bioavailability and metabolism of antiretroviral drugs (36), the need of adequate adherence to complex drug regimens (16, 26), drug toxicities, and the emergence of drug resistance viruses (90), resulting in multi-drug resistance and cross resistance with few or no future therapeutic options. The management of individuals infected with a drug resistant virus who are failing antiretroviral therapy is a major challenge in clinical practice, and is more successful if agents from classes of antiretroviral drugs to which the patient has not previously been exposed are included in the regimen. In the past decade, novel therapies intended to inhibit HIV-1 entry into susceptible cells have been investigated (58), including interference with attachment of the virus to the cell, chemokine co-receptor interaction, and virus-cell membrane fusion (80). Enfuvirtide is the entry inhibitor in the most advanced clinical development. It represents the first of a new class of antiretroviral compounds to demonstrate in vivo potency by targeting a step in viral entry, and was the first drug in its class to be approved for clinical use by the FDA in March 13, 2003 (1). This agent has been shown to provide a benefit when given as part of a salvage regimen for persons with drug-resistant HIV-1, who currently have limited therapeutic options. In this chapter we review, summarize and update the recent scientific data on this drug.
CLASS Chemical Structure Enfuvirtide (T-20, Fuzeon, Pentafuside, DP-178) is a linear 36 amino-acid peptide (molecular mass 4.492 Da) with the following primary amino acid sequence: CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2 (1, 107). This agent is produced synthetically in a process involving more than 100 steps (as compared with eight to 12 steps for a typical anti-HIV medication) to give a powder for subcutaneous (SC) injection (60). The peptide is derived from a naturally occurring motif within the second heptad-repeat domain (HR2) of gp41 transmembrane glycoprotein of a laboratory strain of HIV-1 (LAI) (65). Structure-Activity Relationship Based on the structure, enfuvirtide binds to a region of the gp41 subunit of the HIV-1 envelope glycoprotein (first heptad repeat domain – HR1) that mediates a conformational change required for viral and host-cell membrane fusion. This conformational change is essential to bring the viral and cellular membranes into close enough proximity for fusion and subsequent viral entry into the host-cell. Enfuvirtide prevents this step and thus also the infection of the cell by HIV-1 (see also ‘Mechanisms of Action’ below).
ANTIVIRAL ACTIVITY In the original report which suggested a synthetic gp41 peptide as a potent inhibitor of virus-mediated cell-cell fusion (107), Wild et al. reported a 50% inhibitory concentration (IC50) of approximately 1.7 ng/ml. Since then, in vitro activity of enfuvirtide was examined in CD4+ cells infected with HIV-1 laboratory and clinical isolates. IC50 measurements for enfuvirtide in laboratory and primary isolates representing HIV-1 clades A to G ranged from 18 to 1260 ng/ml, and those for baseline clinical isolates ranged from 0.4 to 480 ng/ml (cMAGI assay), and from 3 to 7530 ng/mL (recombinant phenotypic assay) (1, 62). The viral-host cell fusion process may occur at a range of speeds depending on the concentration of CD4 and co-receptors on cell surfaces (80). This may influence the activity of fusion inhibitors across cell lineages and between individuals. Enfuvirtide was similarly active in-vitro against CCR5, CXCR4, and dual tropic viruses according to some reports (1, 4, 46, 62), whereas others showed higher IC50 values for CCR5 compared with CXCR4 using viruses, suggesting that patients with more advanced disease or harboring CXCR4 isolates may experience a more potent response to enfuvirtide (15, 33, 34). Another aspect, which may affect the antiviral activity of enfuvirtide other than the evolution of drug resistance discussed below, includes the relative affinity of the specific virus gp120 for the chemokine receptor. Initial reports suggest that viruses with higher affinity may spend less time in the transition state where gp41 is exposed for enfuvirtide binding (88). Enfuvirtide has no activity against HIV-2 (1).
MECHANISMS OF ACTION The mechanism of action of enfuvirtide is derived from its composition and design, and is directly associated with the HIV-host cell infecting process. Enfuvirtide interferes with HIV-1 entry into cells by inhibiting fusion of viral and cellular membranes. In order to understand how this drug works, it is important to briefly review the mechanisms of viral binding, fusion and entry into cells. The HIV-1 envelope glycoprotein consists of two non-covalently associated sub-units, the surface subunit gp120 and the transmembrane subunit gp41 which are presented on the lipid bilayer membrane of the virus. In common with other viruses, gp41 contains a short region within its sequence called the ‘fusion peptide’, which is required for mediating membrane fusion (38). The N-terminal section of gp41 includes two highly conserved motifs, comprising of periodic repeats of leucine or isoleucine residues at every seventh position over eight helical turns, termed ‘heptad-repeat’ or ‘leucine zipper’ regions (31, 44). These amino acid sequences termed HR1 and HR2 give the protein periodic hydrophobicity, and are predictive of an α-helical structure within gp41 (12-14). After the initial binding of the viral gp120 subunit to the host cell CD4 and chemokine co-receptors CCR5 and/or CXCR4 (21, 29, 32, 35, 41, 59), gp41 undergoes a change from a configuration where its fusion peptide is pointed inward toward the viral surface, to one where the fusion peptide is sprung outward toward the cell membrane, similar to the mechanism described for influenza virus (11). In this extended gp41 conformation, the intertwined N-terminal HR1 and C-terminal HR2 regions collapse together to form a thermodynamically stable 6-helix configuration that provides the energy necessary for pulling the viral and cell membranes into close proximity, and leads to membrane fusion (42, 61). This is a critical step in the viral life cycle, leading to the penetration of the viral core into the cytoplasm and cell infection (15, 58). Similar to the C-terminal amino-acid residues of the HR2 domain of gp41 (108), enfuvirtide blocks this gp41 change in configuration by mimicking the HR2 domain and binding competitively to the HR1 domain when gp41 is in its extended conformation thus blocking HR1-HR2 fusion (58, 91). This in turn inhibits virus-cell membrane approximation and subsequent fusion and viral entry into target cells (Figure 1).
MECHANISMS OF RESISTANCE Drug resistance is the viral defense mechanism against attempts to suppress its replication, and has been a major obstacle to the success of HIV-1 antiretroviral therapy. Despite a growing arsenal of drugs and the development of potent regimens, a significant amount of patients develop drug resistance and fail therapy. The addition of a new class of drugs, the entry inhibitors of which enfuvirtide is the first, increase our drug arsenal but does not provide a protective shield against the development of resistance to this class as well. Drug resistance arises from mutations in the viral genome, specifically in the regions that encode the molecular targets of therapy. Viruses that carry or develop mutations that confer drug resistance are selected for, and eventually become the predominate population. In HIV RT and protease, these mutations alter the viral enzymes in such a way that their function is no longer or less inhibited by the drug, improving viral replication. An understanding of the genetic changes that render a particular drug ineffective is important to the development of new drugs, to designing the optimal drug combinations, and also for the clinical management of individual patients. The same mechanism is thought to occur in gp41 inhibitors. In persons who have not been exposed to enfuvirtide, studies have reported very little variance in the HR1 domain (amino acids 36-45) in HIV-1 B and non-B subtypes (50, 92, 110, 113). A somewhat larger variance was seen in areas outside this region, the relevance of which needs to be determined (86, 102). In vitro studies including virus passages in increasing concentrations of drug and phenotypic analyses of site-directed mutants have defined a highly conserved three amino acid motif (glycine, isoleucine, valine – GIV, positions 36-38) within the HR1 region of gp41 as critical for the loss of susceptibility to enfuvirtide. Serine replacing glycine at position 36 (G36S) and methionine replacing valine at position 38 (V38M) were particularly noted as important, supporting the proposed association of the two heptad regions of gp41 (91). Further studies have shown that mutations in the entire HR1 domain from position 36 to 45 confer resistance to enfuvirtide (74, 77, 95). These mutations do not seem to have an effect on the fitness of HIV replication in vivo (17). Other mutations or polymorphisms outside this region, such as A50V(6), may be associated with resistance to enfuvirtide, and testing to detect only the HR1 mutations may not be adequate for clinical management of suspected failure (55). Initial in vivo studies in the enfuvirtide phase I trial demonstrated the rapid emergence (within 14 days) of resistance to enfuvirtide, and demonstrated selection for additional mutations (104). In subsequent phase II trials, viral load (VL) patterns after enfuvirtide monotherapy demonstrated an initial decline followed by a gradual return toward baseline values by the end of the 28-day treatment period (56), suggesting the development of resistance and emphasizing the limitations of simply adding enfuvirtide (or any new agent) to an already failing regimen (15). Point mutations in the regions of the fusion protein binding site within gp41 were detected in ~50% of the patients treated with higher enfuvirtide doses in these trials (57). In the phase III enfuvirtide trials, 94% of patients with protocol-defined virologic failure had virus with amino-acid substitutions at the enfuvirtide binding HR1 domain of gp41 (positions 36 to 45), associated with a wide range of decreases (by a factor of five to 401) in phenotypic susceptibility to enfuvirtide (47, 74). Further subgroup analyses found that following enfuvirtide therapy, persons with viral isolates which were more resistant to RT and protease inhibitors had a greater decrease in susceptibility to enfuvirtide, suggesting that the antiviral activity of enfuvirtide is preserved when combined with additional active agents in the regimen (94). Several enfuvirtide-induced mutations were related to changes in CD4 cell count, without a change in HIV-1 VL. Mutations V38A/E and N126K were associated with an increase in CD4 count and others including Q40H and L45M were associated with a CD4 decrease (2, 75). It is unknown why these mutations affect the CD4 cell count without a resulting change in VL, but it is hypothesized that complex viral and immune mediated mechanisms at the fusion site may promote or decrease viral entry leading to preservation or destruction of CD4 cells respectively, but have no effect on plasma VL. Methods to Overcome or Prevent Resistance Monotherapy of antiretroviral drugs leads to the evolution of drug resistance and rapid therapy failure, and enfuvirtide is no exception to that rule as has been discussed above. Similarly to other infecting agents, the best way to decrease the emergence of drug-resistant virus is the simultaneous administration of several agents that interfere with different stages of the virus life cycle. The data on drug resistance from enfuvirtide studies are just now being released, and early reports support this hypothesis. It has been seen that persons with virus isolates with increased resistance to RT and protease inhibitors, have a greater reduction in susceptibility to enfuvirtide (94). This sheds light on the optimal timing to add enfuvirtide to a failing drug regimen, and further data need to be accumulated in order to help define the patient population that would best benefit from this drug and the optimal timing for its administration, that would also prevent the evolution of resistance.
PHARMACOKINETICS Enfuvirtide has been administered as a single or multiple-dose SC injection with pharmacokinetic studies conducted to determine key parameters such as Cmax, AUC, Tmax, half-life and apparent clearance. These studies have been completed in healthy and in HIV-infected persons (1, 79). Absorption In HIV-infected subjects, a single dose of 90 mg SC injection resulted in a Cmax of 4.59 ± 1.5 µg/ml (median Tmax – 8 hours) and an AUC of 55.8 ± 12.1 µg•h/ml. The absolute bioavailability was 84.3% ± 15.5%. When administered as 90 mg twice daily to HIV-infected subjects, steady-state pharmacokinetics yielded, Cmax of 5.0 ± 1.7 µg/ml (median Tmax – 4 hours), Cmin of 3.3 ± 1.6 µg/ml and AUC of 48.7 ± 19.1 µg•h/ml. Distribution At steady state, the volume of distribution was 5.5 ± 1.1 L after a 90 mg SC dose. When examined over a range from 2 to10 µg/ml, enfuvirtide was 92% bound to plasma proteins, primarily albumin with a lower extent of binding to α-1 acid glycoprotein. Routes of Elimination Although mass balance studies have not been completed in humans, the catabolism of enfuvirtide is anticipated to proceed via amino acid breakdown and recycling. However, experiments with human microsomes and hepatocytes indicate that enfuvirtide is hydrolyzed to a deaminated metabolite (M3). The M3 metabolite has been measured in plasma following enfuvirtide administration with an AUC of 2.4% to 15% of the enfuvirtide AUC (1). After a single dose, the plasma half-life of enfuvirtide is 3.8 ± 0.6 hours. Apparent clearance has been determined after single dose (24.8 ± 4.1 mL/h/kg) and twice daily dosing (30.6 ± 10.6 mL/h/kg).
DOSAGE AND ADMINISTRATION Adults and Children Enfuvirtide is a 36-amino acid peptide and oral treatment with it is not feasible. Intravenous and continuous SC infusion have been attempted, however abandoned (56, 57). The recommended dose of enfuvirtide in adults is 90 mg (1 ml) twice daily, injected subcutaneously into the upper arm, anterior thigh or abdomen. Enfuvirtide has been studied as a once daily 180mg SC injection, but this is likely less effective and is not recommended (97). Other formulations have been tested, but are not approved for clinical use (106). Each injection should be given at a site different from the preceding injection site, and only where there is no current injection site reaction from an earlier dose (1, 58). Clinical studies of enfuvirtide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In children 6 through 16 years old, the recommended dosage of enfuvirtide is 2 mg/kg twice daily up to a maximum dose of 90 mg twice daily, and specific guidelines based on body weight are available (1). No data are available yet to establish a dose recommendation of enfuvirtide in pediatric patients below the age of six years. Renal Failure There is no recommended dosage in patients with renal failure, as formal pharmacokinetic studies of enfuvirtide have not been conducted in patients with renal insufficiency. However, analysis of plasma concentration data from subjects in clinical trials indicated that the clearance of enfuvirtide is not affected in patients with creatinine clearance greater than 35 ml/min. The effect of creatinine clearance less than 35 ml/min on enfuvirtide clearance has not been well studied but may not be affected (1, 69). Hepatic Failure Formal pharmacokinetic studies on enfuvirtide have not been conducted in patients with hepatic impairment. Body Composition Data from enfuvirtide clinical trials indicate that females have a plasma clearance that is 20% lower than males after adjusting for body weight. Enfuvirtide clearance decreases with body weight and relative to a 70 kg male, a 40 kg male is expected to have a 20% lower clearance and a 40 kg female a 36% lower clearance (1). Ascites/Edema Formal pharmacokinetic studies on enfuvirtide have not been conducted in patients with ascites/edema. Chronic Diarrhea/Malabsorption No recommended dosage in patients with chronic diarrhea/malabsorption, however because enfuvirtide is administered subcutaneously no dosage changes are anticipated. Malnutrition As mentioned above, lower body weight results in a lower enfuvirtide clearance, but no dosage changes are recommended. Pregnancy Enfuvirtide is classified in category B for pregnant women, as animal studies revealed no evidence of harm to the fetus from its use. There are only several reports of enfuvirtide use during pregnancy, showing conflicting evidence regarding benefit in the prevention of prenatal HIV-1 transmission (10, 22, 76, 105). There are no adequate and well-controlled studies in pregnant women, and this drug should be used during pregnancy only if clearly needed and if benefits outweigh the risks. To monitor maternal-fetal outcomes of pregnant women exposed to enfuvirtide and other antiretroviral drugs, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263. It is not known whether enfuvirtide is excreted in human milk. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breast-feed if they are receiving enfuvirtide (1) ADVERSE EFFECTS
Enfuvirtide is currently given as a small volume, SC
injection. In all studies up to date, the most common adverse effect of enfuvirtide administration has been localized injection site reactions, which
are typically mild but occur in the majority (98%) of patients. Most patients
had their first reaction during the first week, with no evidence of an increase
in the severity of injection-site reactions over time (66,
67, 82, 100).
Thin-walled and needle-free delivery systems that may reduce the severity of
injection-site reactions are being tested for enfuvirtide administration, and
although some benefits are seen, those are costly and may not reduce local
reaction incidence (51, 71, 93). Only small percentages of patients (3%) discontinued treatment with enfuvirtide because of injection-site reactions. Enfuvirtide must be injected subcutaneously. It should not be administered intramuscularly nor intravenously. Injection site reactions can be minimized by varying the sides (abdomen, upper thighs, upper arm). Research continues into ways of minimizing local injection-site reactions and ways of managing them more effectively. In addition to local injection-site reactions, the combined phase III trials safety results showed 78% of patients in the enfuvirtide group and 75% in the control group had had an adverse event that was related to the treatment regimen. Diarrhea, nausea, and fatigue were the most frequently reported treatment-related adverse events in both groups. Peripheral neuropathy and decreased appetite were the only treatment-related adverse events that occurred with a frequency at least five percent higher in the enfuvirtide group than in the control group. Overall, 22 patients in the enfuvirtide group (7%) and eight patients in the control group (5 %) had adverse events with onset before week 24 that led to withdrawal from the study. The most frequent adverse events leading to withdrawal were vomiting and nausea (1% in the enfuvirtide group and 1% in the control group for both). Persons in the enfuvirtide group had a higher rate of pneumonia compared to patients in the control group (50 patients-6% vs.1 patient-0.3%). It is unclear if the increased incidence of pneumonia is related to enfuvirtide use, however because of this finding, patients with HIV infection should be carefully monitored for signs and symptoms of pneumonia, especially if they have underlying conditions which may predispose them to pneumonia such as low initial CD4 cell counts, high initial VL levels, intravenous drug use, smoking, and a prior history of lung disease (1). Sepsis also occurred more frequently in the combined enfuvirtide group (2% vs. 1%), but the exposure-adjusted rates were not significantly different. Hypersensitivity reactions that may recur with re-challenge have been associated with enfuvirtide therapy. These reactions have included individually and in combination: rash, fever, nausea and vomiting, chills, rigors, hypotension, and elevated serum liver transaminases. Other adverse events that may be immune mediated and have been reported in subjects receiving enfuvirtide include primary immune complex reaction, respiratory distress, glomerulonephritis, and Guillian-Barre syndrome. Risk factors that may predict the occurrence or severity of hypersensitivity to enfuvirtide have not been identified (1). Treatment-related eosinophilia (>700 cells/ml) occurred in a greater proportion of patients in the enfuvirtide group (11% vs. 2%). Review of the cases of individual patients with eosinophilia did not reveal any clinical events suggestive of systemic hypersensitivity (1). There were five deaths during the phase III enfuvirtide studies, all of which were related to the progression of HIV disease and were not considered to be attributable to enfuvirtide administration. Overall, studies report that the degree of satisfaction of patients receiving SC enfuvirtide is good (23, 24). Enfuvirtide had little impact on activities of daily living and most patients stated that they would choose to continue with the drug, and that the need to deliver it via twice-daily SC injections was not considered an important barrier. Patients surveyed found the injections were ‘easy’ or ‘very easy’ to self-administer in 67% of cases, and found aspects of drug storage (81%), medication preparation (71%), and needle and vial disposal (94%) also ‘easy’ or ‘very easy’. Overdoses There are no reports of human experience of acute overdose with enfuvirtide. The highest dose administered to humans in a clinical trial was SC 180 mg as a single dose. There is no specific antidote for overdose with enfuvirtide, and treatment of overdose should consist of general supportive measures (1).
MONITORING REQUIREMENTS Therapeutic Drug Monitoring Data on therapeutic drug monitoring of enfuvirtide are slowly emerging, demonstrating enfuvirtide levels lower and more variable than expected, necessitating further research(96). Other Laboratory Monitoring Enfuvirtide does not appear to interfere with intracellular pathways and is therefore expected to be associated with fewer metabolic complications than existing treatments (18). Clinically meaningful changes in laboratory parameters in persons receiving enfuvirtide, which are potentially related to it, are rare and include leukopenia, anemia, increased amylase level, hyperlipidemia and elevated liver enzymes (66, 67).
DRUG INTERACTIONS In an in vitro human microsomal study, enfuvirtide at 90 mg twice daily did not inhibit CYP450 enzymes. In an in vivo human metabolism study enfuvirtide did not alter the metabolism of CYP3A4, CYP2D6, CYP1A2, CYP2C19 or CYP2E1 substrates (1). Enfuvirtide is indicated for use in HIV infected persons in combination with highly active antiretroviral therapy (HAART) regimens, which commonly include drugs that are substrates, inhibitors and/or inducers of cytochrome P450 isozymes. Furthermore, many HIV-1 infected persons have co-infections and concurrent diseases requiring the concomitant use of additional drugs. In pharmacokinetic interaction studies, no clinically relevant drug-drug interactions occurred when enfuvirtide was co-administered with ritonavir, ritonavir/saquinavir or rifampin, confirming the low potential for metabolic drug-drug interactions involving enfuvirtide (1, 8). Enfuvirtide exhibited additive to synergistic in vitro effects when combined with individual members of various antiretroviral classes, including zidovudine, lamivudine, nelfinavir, indinavir, and efavirenz (1, 3, 98). The fusion process may occur at a range of speeds depending on the concentration of CD4 and co-receptors on cell surfaces. This may influence the activity of fusion inhibitors across cell lineages and between individuals. Inhibitors of co-receptors, another class of entry inhibitors, slow the fusion process, hence are highly synergic with fusion inhibitors, providing an insight into potential future combination therapies (80, 83, 99, 101).
CLINICAL INDICATIONS Enfuvirtide is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy (1). In adults, preliminary phase I and II studies in persons receiving enfuvirtide set the optimal dosing and administration parameters (90 mg twice daily in a SC injection). These studies demonstrated potent, dose-related immunologic and virologic response, without clinically significant short-term toxic effects, demonstrating that drugs with this mechanism of action are feasible options for treating HIV-1 infecting persons failing current antiretroviral therapy(56, 57, 64, 65). Subsequent clinical data demonstrate continued efficacy and safety (20, 37, 52, 84, 89) (Table 1). The 24-week results of two parallel pivotal phase III studies of enfuvirtide (TORO 1 and TORO 2), in patients with extensive previous treatment, were initially reported (Table 1). One (66) involved 491 HIV-infected subjects in North-America and Brazil and the other (67) involved 504 HIV-infected subjects in Europe and Australia. These were randomized open-label studies, and all participants were treatment experienced and/or had documented resistance to each of the three classes of currently available RT and protease inhibitors. Upon study entry subjects received optimized background regimens (using genotypic and phenotypic testing), and then were randomly assigned to receive or not to receive 90 mg of enfuvirtide twice daily. At week 24, the combined mean reductions in VL (1.55 log10 copies/ml in enfuvirtide recipients compared with 0.71 log10 copies/ml in the controls) and increases in CD4 (71 cells/ml in enfuvirtide recipients compared with 35 cells/ml in the controls) significantly favored enfuvirtide recipients. The percentage of patients with protocol-defined virologic failure was much lower in the enfuvirtide groups than in the control groups (46% vs. 71%). However, only 20% of patients who received enfuvirtide achieved a VL of less than 50 copies/ml after 24 weeks of therapy (43). The durability of response to enfuvirtide was evaluated at both 48 and 96 weeks of the TORO clinical trials(84, 89). At 48 weeks, compared to the placebo group, more patients in the enfuvirtide group continued to show a significant decline in VL (37% versus 17%) and longer median time to protocol-defined virologic failure (52% versus 78%). However, only 18% of patients who received enfuvirtide achieved VL <50 copies/ml, compared to 8% in the placebo group(84). At 96 weeks evaluation included patients who had originally been on enfuvirtide as well as those who had switched to the study drug from placebo at 48 weeks, but did not necessarily meet criteria for virologic failure. By 96 weeks, 18% had achieved a VL <50 copies/ml and 27% a VL <400 copies/ml. More favorable responses were seen in patients originally on enfuvirtide versus the switch group, with 166 vs. 116 cells/mm3 mean CD4 increase, and -2.1 vs. -1.1 log10 copies/ml VL decline. These data demonstrate durable efficacy and safety of enfuvirtide over 96 weeks and suggest that treatment with enfuvirtide in combination with other agents for the treatment of antiretroviral-experienced HIV-infected patients may be more beneficial early in salvage therapy (89). Other cohort studies have confirmed the benefit of enfuvirtide seen in these early clinical trials (6, 70). Enfuvirtide has a pivotal role in optimizing response to new drug combinations. Two trials evaluated sub-populations of patients treated with enfuvirtide in combination with ritonavir boosted protease inhibitors with an optimized background regimen. In the RESIST-1 and 2 trials (52), enfuvirtide was given as part of the background regimen with or without the novel protease inhibitor tipranavir. In a subgroup 96-week analysis, there was significantly more undetectable VL in patients taking enfuvirtide versus no enfuvirtide, 35% and 14% respectively(45), although patients taking enfuvirtide had different baseline CD4 and VL characteristics. In the POWER 1 and 2 studies, examining the performance of ritonavir boosted darunavir in treatment-experienced patients with protease inhibitor resistance(20), similar results were seen, with an increased number of patients taking enfuvirtide versus no enfuvirtide with a VL <50 copies/ml at 48 weeks (58% and 44% respectively (53, 111). Taken in context with the TORO trials, these data suggest that addition of enfuvirtide to a ritonavir boosted protease inhibitor regimen may have significant impact on VL and CD4 counts. This evidence led to guidelines recommendation of a VL<50 copies/mL as an appropriate treatment goal in treatment-experienced populations (40, 49). Similar results have been obtained with integrase inhibitors (48) and are being collected with etravirine, a new NNRTI inhibitor in the DUET trials (68, 72). Enfuvirtide has been studied as part of multi-drug regimens with varying combinations of antiretrovirals. The addition of enfuvirtide increased antiviral potency of a highly active four-drug regimen in antiretroviral-naďve patients (78), and showed significant VL and CD4 improvements in an NRTI-sparing regimen (37) and in NNRTI-naďve patients (64). However, another study demonstrated that the viral decay dynamics did not appear to change when enfuvirtide was added to a saquinavir/ritonavir or efavirenz based regimen (9). The clinical implications of those findings are unclear. A number of studies have looked at predictors of virologic suppression with enfuvirtide. In the TORO-1 and 2 trials, favorable VL and CD4 responses at week 12 were shown to predict a better response in triple-class experienced patients at weeks 24, 48, and 96(87). In fact, only 1% with detectable VL at week 12 achieved VL <50 copies/ml at 48 and 96 weeks. However, even in the setting of incomplete viral suppression, enfuvirtide still has measurable antiviral activity and increases in VL are seen as a result of discontinuation (7, 30). Studies evaluating the use of enfuvirtide in children (3-16 years) have also been reported, although in smaller numbers (Table 2). At adjusted doses, safety, tolerability and potency were similar to those seen in adults (5, 18, 19, 25, 39, 109, 112). As new gp41 inhibitors are being explored (27, 28), enfuvirtide will likely be used as the ‘anchor’ drug in salvage therapy regimens for patients who have failed several conventional combination therapies or have been infected with drug-resistant virus, in whom gp41 inhibitors are considered. Current guidelines state that if several potent drugs other than enfuvirtide are available, it may be best to defer enfuvirtide use until it becomes only one of two available and fully active drugs. However, since the goal of therapy is to achieve VL <50 copies/mL, enfuvirtide may be considered to achieve this degree of success among experienced patients(49). Further studies are needed to better define its role in other patient populations, including those with double-class experience, pediatric patients, prevention of mother-to-child-transmission, and prevention of HIV transmission to healthcare workers (15). Future use of enfuvirtide will likely be affected by cost, inconvenience, and the availability of drugs with new mechanisms of action that might provide similar treatment effects for patients with widespread drug resistance (40). More extensive and prolonged clinical trials and quality of life studies are needed to establish the best positioning of enfuvirtide in the current therapeutic guidelines of HIV disease and its future role, besides its current approval for salvage therapy of adult and pediatric HIV-infected patients with limited therapeutic options (73).
TABLES AND FIGURES Table 1. Clinical Studies Involving Enfuvirtide Administration in HIV-1 Infected AdultsTable 2. Clinical Studies Involving Enfuvirtide Administration in HIV-1 Infected Children Figure 1: Proposed mechanism of T-20 action. (Reprinted with permission of Nature Publishing Group, Nature Medicine, Vol. 4, Issue 11, 1998, by J. Michael Kilby, et al).
1. Fuzeon. FDA Drug Approvals List. In; 2003. 2. Aquaro S, D'Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, Santoro M, Bertoli A, Mazzotta F, Bonora S, Tozzi V, Bellagamba R, Zaccarelli M, Narciso P, Antinori A, Perno CF. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006;58(4):714-22. [PubMed] 3. Barney S, Guthrie K, Davis D, Hopkins S, Johnson MR, Lambert DM. Pentafuside (T20), a novel inhibitor of HIV-1 fusion and infection, is synergistic when used in combination with reverse transcriptase (RT) and protease inhibitors in vitro. Antivir Res 1998;37(3):Abst 48. 4. Barretina J, Blanco J, Bonjoch A, Llano A, Clotet B, Este JA. Immunological and virological study of enfuvirtide-treated HIV-positive patients. Aids 2004;18(12):1673-82. 5. Bellibas SE, Siddique Z, Dorr A, Bertasso A, Sista P, Kolis SJ, Cotler S, Delora P. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 2004;23(12):1137-41. [PubMed] 6. Bienvenu B, Krivine A, Rollot F, Pietri MP, Lebault V, Meritet JF, Guerin C, Spiridon G, Salmon D, Guillevin L, Lebon P, Launay O. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice. J Med Virol 2006;78(10):1312-7. [PubMed] 7. Bonjoch A, Negredo E, Puig J, Erkizia I, Puig T, Cabrera C, Ruiz L, Clotet B. Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide. Aids 2006;20(14):1896-8. [PubMed] 8. Boyd M, Ruxrungtham K, Zhang X, Bellibas SE, Buss NE, Patel IH. Enfuvirtide-investigation on the drug interaction potential in HIV infected patients. In: 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14, 2003; Boston, MA, USA; 2003. p. Abstract 541. 9. Boyd MA, Dixit NM, Siangphoe U, Buss NE, Salgo MP, Lange JM, Phanuphak P, Cooper DA, Perelson AS, Ruxrungtham K. Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). J Infect Dis 2006;194(9):1319-22. [PubMed] 10. Brennan-Benson P, Pakianathan M, Rice P, Bonora S, Chakraborty R, Sharland M, Hay P. Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. Aids 2006;20(2):297-9.[PubMed] 11. Carr CM, Kim PS. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 1993;73(4):823-32. [PubMed] 12. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89(2):263-73. [PubMed] 13. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998;93(5):681-4. [PubMed] 14. Chen CH, Matthews TJ, McDanal CB, Bolognesi DP, Greenberg ML. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol 1995;69(6):3771-7. [PubMed] 15. Chen RY, Kilby JM, Saag MS. Enfuvirtide. Expert Opin Investig Drugs 2002;11(12):1837-43. [PubMed] 16. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003;17(4):169-77. [PubMed] 17. Chibo D, Roth N, Roulet V, Skrabal K, Gooey M, Carolan L, Nicholls J, Papadakis A, Birch C. Virological fitness of HIV in patients with resistance to enfuvirtide. Aids 2007;21(14):1974-7. [PubMed] 18. Church JA, Cunningham C, Hughes M, Palumbo P, Mofenson LM, Delora P, Smith E, Wiznia A, Purdue L, Hawkins E, Sista P. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2002;21(7):653-9. [PubMed] 19. Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora P, Smith E, Wiznia A, Hawkins E, Sista P, Cunningham CK. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2004;23(8):713-8. [PubMed] 20. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wohrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369(9568):1169-78. [PubMed] 21. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV- suppressive factors produced by CD8+ T cells. Science 1995;270(5243):1811-5. [PubMed] 22. Cohan D, Feakins C, Wara D, Petru A, McNicholl I, Schillinger D, Lu J, Kuritzkes D, Deeks SG. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. Aids 2005;19(9):989-90. [PubMed] 23. Cohen CJ, Dusek A, Green J, Johns EL, Nelson E, Recny MA. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV- infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS 2002;16(7):327-35. [PubMed] 24. Cullell-Young M, Leeson PA, del Fresno M, Bayes M. Enfuvirtide. Drugs of the Future 2002;27(5):450-457. 25. Cunningham C, Church J, Hughes M, Sista P, Palumbo P, Mofenson L, Delora P, Aweeka F, Soy D, Sheiner L. Chronic subcutaneous T-20 (Enfuvirtide) in HIV infected children: 48 week outcome. In: 40th Annual meeting of the Infectious Diseases Society of America; 2002 October 24-27, 2002; Chicago, IL, USA; 2002. p. Abstract 441. 26. Daar ES, Cohen C, Remien R, Sherer R, Smith K. Improving adherence to antiretroviral therapy. AIDS Read 2003;13(2):81-2, 85-6, 88-90. [PubMed] 27. Dai S, Song H, Dou G, Qian X, Zhang Y, Cai Y, Liu X, Tang Z. Quantification of sifuvirtide in monkey plasma by an on-line solid-phase extraction procedure combined with liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19(10):1273-82. [PubMed] 28. Dai SJ, Dou GF, Qiang XH, Song HF, Tang ZM, Liu DS, Liu XW, Yang LM, Zheng YT, Liang Q. Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro. Acta Pharmacol Sin 2005;26(10):1274-80. [PubMed] 29. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312(5996):763-7. [PubMed] 30. Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, Liegler T, Hunt P, Martin JN, Kuritzkes DR. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2007;195(3):387-91. [PubMed] 31. Delwart EL, Mosialos G, Gilmore T. Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat. AIDS Res Hum Retroviruses 1990;6(6):703-6. [PubMed] 32. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381(6584):661-6. [PubMed] 33. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000;74(18):8358-67. [PubMed] 34. Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner L, Shaw GM, Hunter E. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001;75(18):8605-14. [PubMed] 35. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC- CKR-5. Nature 1996;381(6584):667-73. [PubMed] 36. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38(1):41-57. [PubMed] 37. Dwyer DE, Workman C, Hales G, Amin J, Cooper D, Miller J. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study. Antivir Ther 2006;11(4):409-19. [PubMed] 38. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001;70:777-810. [PubMed] 39. Eralp Bellibas S, Pepper T, Dorr A, Bertasso A, Sista P, Duff F, Kolis S, Delora P. Pharmacokinetics and safety on 2 mg/kg enfuvirtide (T-20) in combination therapy in HIV-infected children and adolescents. In: 14th International AIDS Conference; 2002 July 7-12, 2002; Barcelona, Spain; 2002. p. Abstract TuPeB4632. 40. Este JA, Telenti A. HIV entry inhibitors. Lancet 2007;370(9581):81-8. [PubMed] 41. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272(5263):872-7. [PubMed] 42. Ferrer M, Kapoor TM, Strassmaier T, Weissenhorn W, Skehel JJ, Oprian D, Schreiber SL, Wiley DC, Harrison SC. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 1999;6(10):953-60. [PubMed] 43. Fletcher CV. Enfuvirtide, a new drug for HIV infection. Lancet 2003;361(9369):1577-8. [PubMed] 44. Gallaher WR, Ball JM, Garry RF, Griffin MC, Montelaro RC. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 1989;5(4):431-40. [PubMed] 45. Gazzard B, Antinori A, Cheli C, Neubacher D. Combined analysis of RESIST 96 week data: durability and efficacy of tipranavir/r in treatment-experienced patients. In: 8th International Congress on Drug Therapy in HIV Infection; 2006 12–16 November 2006; Glasgow, UK; 2006. p. P23. 46. Greenberg ML, McDanal C, Stanfield-Oakley SA, Jin L, Tremblay CL, Sista P, Hirsch M, Matthews T. Virus sensitivity to T-20 and T-1249 is independant of coreceptor usage. In: 8th Conference on Retroviruses and Opportunistic Infections; 2001 February 4-8, 2001; Chicago, IL, USA; 2001. p. Abstract 473. 47. Greenberg ML, Melby T, Sista P, DeMasi R, Cammack N, Salgo M, Whitcomb J, Petropoulos C, Matthews T. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks. In: 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14, 2003; Boston, MA, USA; 2003. p. Abstract 141. 48. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369(9569):1261-9. [PubMed] 49. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Jama 2006;296(7):827-43. [PubMed] 50. Hanna SL, Yang C, Owen SM, Lal RB. Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide [corrected]. Aids 2002;16(12):1603-8. [PubMed] 51. Harris M, Joy R, Larsen G, Valyi M, Walker E, Frick LW, Palmatier RM, Wring SA, Montaner JS. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). Aids 2006;20(5):719-23. [PubMed] 52. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006;368(9534):466-75. [PubMed] 53. Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007;8(4):259-64. [PubMed] 54. Hoetelmans RM. Sanctuary sites in HIV-1 infection. Antivir Ther 1998;3(Suppl 4):13-7. [PubMed] 55. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007;15(4):119-25. [PubMed] 56. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat.Med. 1998;4:1302-1307. [PubMed] 57. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002;18(10):685-93. [PubMed] 58. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003;348(22):2228-38. [PubMed] 59. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, Montagnier L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984;312(5996):767-8. [PubMed] 60. LaBonte J, Lebbos J, Kirkpatrick P. Enfuvirtide. Nat Rev Drug Discov 2003;2(5):345-6. [PubMed] 61. LaBranche CC, Galasso G, Moore JP, Bolognesi DP, Hirsch MS, Hammer SM. HIV fusion and its inhibition. Antiviral Res 2001;50(2):95-115. [PubMed] 62. Labrosse B, Labernardiere JL, Dam E, Trouplin V, Skrabal K, Clavel F, Mammano F. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol 2003;77(2):1610-3. [PubMed] 63. Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Differences in the detection of three HIV-1 protease inhibitors in non- blood compartments: clinical correlations. HIV Clin Trials 2002;3(1):27-35. [PubMed] 64. Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 2003;8(4):279-87. [PubMed] 65. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003;17(5):691-8. [PubMed] 66. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Jr., Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348(22):2175-85. [PubMed] 67. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348(22):2186-95. [PubMed] 68. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):39-48. [PubMed] 69. Leen C, Wat C, Nieforth K. Pharmacokinetics of enfuvirtide in a patient with impaired renal function. Clin Infect Dis 2004;39(11):e119-21. [PubMed] 70. Loutfy MR, Antoniou T, Shen S, Diong C, Vlaicu M, Halpenny R, Kovacs C, Fletcher D, Raboud JM. Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting. HIV Clin Trials 2007;8(1):36-44. [PubMed] 71. Loutfy MR, Harris M, Raboud JM, Antoniou T, Kovacs C, Shen S, Dufresne S, Smaill F, Rouleau D, Rachlis A, Gough K, Lalonde R, Tsoukas C, Trottier B, Walmsley SL, Montaner JS. A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. HIV Med 2007;8(7):427-32. [PubMed] 72. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):29-38. [PubMed] 73. Manfredi R, Sabbatani S. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20). Curr Med Chem 2006;13(20):2369-84. [PubMed] 74. Melby T, Sista P, DeMasi R, Kirkland T, Roberts N, Salgo M, Heilek-Snyder G, Cammack N, Matthews TJ, Greenberg ML. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006;22(5):375-85. [PubMed] 75. Melby TE, Despirito M, Demasi RA, Heilek G, Thommes JA, Greenberg ML, Graham N. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. Aids 2007;21(18):2537-9. [PubMed] 76. Meyohas MC, Lacombe K, Carbonne B, Morand-Joubert L, Girard PM. Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough. Aids 2004;18(14):1966-8. [PubMed] 77. Mink M, Greenberg ML, Mosier S, Jannumpalli S, Davison D, Jin L, Melby T, Sista P, Lambert D, Cammack N, Salgo M, Matthews T. Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T-20 (enfuvirtide) in vitro: analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3. Antivir Ther 2002;7 supplement 1:S24. 78. Molto J, Ruiz L, Valle M, Martinez-Picado J, Bonjoch A, Bravo I, Negredo E, Heilek-Sneider GM, Clotet B. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients. Antivir Ther 2006;11(1):47-51. [PubMed] 79. Mould DR, Zhang X, Nieforth K, Salgo M, Buss N, Patel IH. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2005;77(6):515-28. [PubMed] 80. Moyle G. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. J Antimicrob Chemother 2003;51(2):213-7. [PubMed] 81. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135(1):17-26. [PubMed] 82. Myers SA, Selim AA, McDaniel MA, Hall R, Zhang Y, Bartlett JA, True AL. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. Antivir Ther 2006;11(7):935-9. 83. Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001;183(7):1121-5. [PubMed] 84. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Jr., Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40(4):404-12. [PubMed] 85. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-60. [PubMed] 86. Poveda E, Rodes B, Toro C, Martin-Carbonero L, Gonzalez-Lahoz J, Soriano V. Evolution of the gp41 env region in HIV-infected patients receiving T- 20, a fusion inhibitor. Aids 2002;16(14):1959-61. [PubMed] 87. Raffi F, Katlama C, Saag M, Wilkinson M, Chung J, Smiley L, Salgo M. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 2006;42(6):870-7. [PubMed] 88. Reeves JD, Puffer B, Ahmad N, Derdeyn CA, Sarron M, Edwards T, Carlin D, Harvey PE, Pierson T, Hunter E, Doms RW. Use of entry inhibitors to probe envelope: receptor interactions. In: 9th Conference on Retroviruses and Opportunistic Infections; 2002 February 24-28, 2002; Seattle, WA, USA; 2002. p. Abstract 82. 89. Reynes J, Arasteh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, M OH, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007;21(8):533-43. [PubMed] 90. Richman D, Bozzette S, Morton S, Chien S, Wrin T, Dawson K, Hellmann N. The prevalence of antiretroviral drug resistance in the US. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago, IL; 2001. p. Abstract LB-17. 91. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41- derived inhibitory peptides. J Virol 1998;72(2):986-93. [PubMed] 92. Roman F, Gonzalez D, Lambert C, Deroo S, Fischer A, Baurith T, Staub T, Boulme R, Arendt V, Schneider F, Hemmer R, Schmit J-C. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 2003;33:134-139. [PubMed] 93. Shalit P, True A, Thommes JA. Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study. HIV Clin Trials 2007;8(1):24-35. [PubMed] 94. Sista P, Melby T, Greenberg ML, DeMasi R, Kuritzkes D, Nelson M, Petropoulos C, Salgo M, Cammack N, Matthews T. Subgroup analysis of baseline susceptibility and early virological response to enfuvirtide in the combined TORO studies. In: 12th International HIV Drug Resistance Workshop; 2003 June 10-14, 2003; Cabo del Sol, Los Cabos, Mexico; 2003. p. Abstract 55. 95. Sista PR, Melby T, Davison D, Jin L, Mosier S, Mink M, Nelson EL, DeMasi R, Cammack N, Salgo MP, Matthews TJ, Greenberg ML. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. Aids 2004;18(13):1787-94. [PubMed] 96. Stocker H, Kloft C, Plock N, Breske A, Kruse G, Herzmann C, Schulbin H, Kreckel P, Weber C, Goebel F, Roeling J, Staszewski S, Plettenberg A, Moecklinghoff C, Arasteh K, Kurowski M. Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrob Agents Chemother 2006;50(2):667-73. [PubMed] 97. Thompson M, DeJesus E, Richmond G, Wheeler D, Flaherty J, Piliero P, True A, Chiu YY, Zhang Y, McFalls E, Miralles GD, Patel IH. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects. Aids 2006;20(3):397-404. [PubMed] 98. Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch M. In Vitro synergy observed between the fusion inhibitor T-20 and a CCR5 inhibitor TAK-779. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 September 17-20, 2000; Toronto, Canada; 2000. p. Abstract 1164. 99. Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000;25(2):99-102. [PubMed] 100. Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arasteh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ, Jr., Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005;40(4):413-21. [PubMed] 101. Van der Ryst E, Cooper D, Konourina I, Saag M, Goodrich J, Tawadrous M, Simpson P, Sullivan J, Westby M, Mayer M. Efficacy of maraviroc in combination with at least one other potent new antiretroviral drug: 24-week combined analysis of the MOTIVATE 1 and 2 studies. In: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2007 July 22-25, 2007; Sydney, Australia; 2007. p. Abstract WEPEB115LB. 102. Villahermosa ML, Perez-Alvarez L, Carmona R, Cuevas MT, Thomson MM, Medrano L, Vazquez de Parga E, Delgado E, Pedreira JD, Najera R. Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants. Aids 2003;17(7):1083-6. [PubMed] 103. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999;179(3):717-20. [PubMed] 104. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46(6):1896-905. [PubMed] 105. Wensing AM, Boucher CA, van Kasteren M, van Dijken PJ, Geelen SP, Juttmann JR. Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. Aids 2006;20(10):1465-7. [PubMed] 106. Wheeler DA, Lalezari JP, Kilby JM, Wheat J, Delehanty J, DeMasi R, Patel I, Salgo M. Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients. J Clin Virol 2004;30(2):183-90. [PubMed] 107. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus- mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9(11):1051-3. [PubMed] 108. Wild C, Dubay JW, Greenwell T, Baird T, Jr., Oas TG, McDanal C, Hunter E, Matthews T. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus- induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A 1994;91(26):12676-80. [PubMed] 109. Wiznia A, Church J, Emmanuel P, Eppes S, Rowell L, Evans C, Bertasso A. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J 2007;26(9):799-805. [PubMed] 110. Xu L, Hue S, Taylor S, Ratcliffe D, Workman JA, Jackson S, Cane PA, Pillay D. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and experienced patients. Aids 2002;16(12):1684-6. [PubMed] 111. Youle M, Staszweski S, Clotet B, Arribas JR, Blaxhult A, Carosi G, Dejesus E, Di Perri G, Estrada V, Fisher M, Kovacs C, Kulasegaram R, Lazzarin A, Marriott D, Munoz L, Reynes J, Shalit P, Slim J, Tsoukas C, Vaccaro A, Vera J. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. HIV Clin Trials 2006;7(2):86-96. [PubMed] 112. Zhang X, Lin T, Bertasso A, Evans C, Dorr A, Kolis SJ, Salgo M, Patel I. Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. J Clin Pharmacol 2007;47(4):510-7. [PubMed] 113. Zollner B, Feucht HH, Schroter M, Schafer P, Plettenberg A, Stoehr A, Laufs R. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. Aids 2001;15(7):935-6. [PubMed] |
|